- Home
- STSS vs MYNZ Comparison
STSS vs MYNZ Comparison
Compare STSS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- MYNZ
- Stock Information
- Founded
- STSS 2017
- MYNZ 2021
- Country
- STSS United States
- MYNZ Germany
- Employees
- STSS N/A
- MYNZ N/A
- Industry
- STSS Medical/Dental Instruments
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- MYNZ Health Care
- Exchange
- STSS Nasdaq
- MYNZ Nasdaq
- Market Cap
- STSS 5.5M
- MYNZ 5.5M
- IPO Year
- STSS 2022
- MYNZ 2021
- Fundamental
- Price
- STSS $5.73
- MYNZ $1.92
- Analyst Decision
- STSS
- MYNZ Buy
- Analyst Count
- STSS 0
- MYNZ 2
- Target Price
- STSS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- STSS 149.1K
- MYNZ 154.3K
- Earning Date
- STSS 08-13-2025
- MYNZ 07-22-2025
- Dividend Yield
- STSS N/A
- MYNZ N/A
- EPS Growth
- STSS N/A
- MYNZ N/A
- EPS
- STSS N/A
- MYNZ N/A
- Revenue
- STSS N/A
- MYNZ $893,991.00
- Revenue This Year
- STSS N/A
- MYNZ $26.06
- Revenue Next Year
- STSS N/A
- MYNZ $4.97
- P/E Ratio
- STSS N/A
- MYNZ N/A
- Revenue Growth
- STSS N/A
- MYNZ N/A
- 52 Week Low
- STSS $3.36
- MYNZ $1.34
- 52 Week High
- STSS $2,224.20
- MYNZ $20.08
- Technical
- Relative Strength Index (RSI)
- STSS 45.95
- MYNZ 57.87
- Support Level
- STSS $5.51
- MYNZ $1.35
- Resistance Level
- STSS $5.95
- MYNZ $2.15
- Average True Range (ATR)
- STSS 0.32
- MYNZ 0.13
- MACD
- STSS 0.20
- MYNZ 0.10
- Stochastic Oscillator
- STSS 66.25
- MYNZ 71.67
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.